Although guselkumab, a selective IL-23 inhibitor, and secukinumab and ixekizumab, monoclonal antibodies targeting IL-17A, were highly effective in treating psoriasis, their treatment results in IBD were not consistent. Here, IL17A is linked to inflammatory bowel disease.